Skip to content

Controlled Study on the Effectiveness of a Dutch Can Do Training (CDT) in People with Relapsing Remitting Multiple Sclerosis

Controlled Study on the Effectiveness of a Dutch Can Do Training (CDT) in People with Relapsing Remitting Multiple Sclerosis - Controlled Dutch Can Do Training (CDT) Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON39648
Enrollment
200
Registered
2013-02-11
Start date
2013-03-07
Completion date
Unknown
Last updated
2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis

Interventions

CDT consists of training programs tailored to the personalized goals of the individual participants. The training is given by a team of experienced healh care professionals (neurologisct, MS-special

Sponsors

Nationaal MS Fonds
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: For people with multiple sclerosis (MS): 1) diagnosis Relapsing Remitting MS since 1 year or longer, 2) Expanded Disability Status Scale (EDSS) score less than or equal to 4.0, 3) no symptoms suggestive of a relapse, 4) no relapse in the previous 4 weeks, 5) willing and capable to participate in the investigations mentioned in the study protocol. For partners of people with MS: willing and capable to participate in the investigations mentioned in the study protocol.

Exclusion criteria

Exclusion criteria: 1) Progressive type of multiple sclerosis (MS), 2) Diagnosis MS since less than 1 year, 3) Expanded Disability Status Scale (EDSS) score less higher than 4.0, 4) Symptoms suggestive of a relapse, 5) Relapse in last 4 weeks, 6) not capable to participate in the investigations mentioned in the study protocol.

Design outcomes

Primary

MeasureTime frame
Self-efficacy-control, as measured by the Multiple Sclerosis Self-Efficacy-18 control score.

Secondary

MeasureTime frame
Self-efficacy-function, MSSES-18 (function score); Problem-related autonomy, Impact on Participation and Autonomy (IPA-32) problem-related score; Limitations-related autonomy, IPA-32 limitations-score; health-related quality of life, Multiple Sclerosis Quality of Life-54 (MSQoL-54) questionnaire (mental and physical scores); anxiety and depression, Hospital Anxiety and Depression Scale-14 (HADS-14) (anxiety and depression scores); cost effectiveness and cost utility, EQ-5D-5L, costs questionnaire; neurological symptoms and handicap, Expanded Disability Status Scale (EDSS) (only 1 week before CDT).

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)